搜索筛选:
搜索耗时1.5305秒,为你在为你在102,285,761篇论文里面共找到 2 篇相符的论文内容
发布年度:
Efficacy and safety of anlotinib plus S-1as thirdly-line or later-line treatmentin advanced non-smal
[期刊论文] 作者：Heng Cao,Kai Liang,Peng Liu,Ji,
来源：肿瘤学与转化医学:英文版 年份：2020
Objective Anlotinib,an oral vascular endothelial growth factor receptor 2(VEGFR2)inhibitor,has confirmed antitumor activity in lung cancer in both in vitro and...
Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-sm
[期刊论文] 作者：Heng Cao,Kai Liang,Peng Liu,Jing Wang,Yuanyuan Ji,Lujuan Xu,Weilong Wu,Shengnan Guo,Xuekun Song,Yonggui,
来源：肿瘤学与转化医学（英文） 年份：2020
Objective Anlotinib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, has confirmed antitumor activity in lung cancer in both in vitro...
相关搜索：
